ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Early macular choroidal hemodynamic changes after faricimab loading in treatment-naïve diabetic macular edema.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the early macular choroidal hemodynamic changes induced by faricimab loading in treatment-naïve diabetic macular edema (DME) and to determine potential systemic crossover effects by comparing faricimab-injected eyes with the contralateral non-injected eyes.
methodsThis retrospective, single-center cohort study analyzed data of a total of 92 eyes from 46 treatment-naïve patients with DME. All patients received three consecutive monthly intravitreal faricimab injections in the study eye. The primary outcome was the longitudinal change in macular choroidal blood flow (CBF) in injected and contralateral non-injected eyes, together with changes in central retinal thickness (CRT) and subfoveal choroidal thickness (SFCT). Macular CBF was quantified as mean blur rate (MBR) using laser speckle flowgraphy. Data were analyzed using a linear mixed-effects model.
resultsIn the 46 injected eyes, faricimab treatment resulted in significant monthly decreases in CRT and SFCT. This anatomical improvement was accompanied by a modest but statistically significant reduction in macular CBF, whereas ocular perfusion pressure remained stable. Visual acuity significantly improved. In contrast, no significant changes occurred in macular CBF, CRT, or SFCT in the 46 contralateral non-injected eyes.
conclusionInitial faricimab loading therapy yielded marked anatomical improvements with only modest changes in macular choroidal perfusion in treatment-naïve DME. No measurable changes were detected in the contralateral non-injected eyes, suggesting that the early effects of faricimab are predominantly localized to the treated eye.
Indexed as
Identifiers
42118247What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.